Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Average Recommendation of "Buy" from Brokerages

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) has earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock in the last year is $42.67.

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, May 14th.

Insider Activity

In related news, insider Tracey Sacco sold 5,000 shares of the business's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total value of $164,150.00. Following the transaction, the insider now owns 71,750 shares in the company, valued at $2,355,552.50. The trade was a 6.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Katie Peng sold 1,006 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. The trade was a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 154,798 shares of company stock valued at $5,482,238 in the last ninety days. 13.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Scholar Rock in the fourth quarter valued at $274,000. Blackstone Inc. purchased a new stake in shares of Scholar Rock during the 4th quarter worth $910,000. Rhumbline Advisers grew its stake in shares of Scholar Rock by 13.2% during the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after purchasing an additional 13,247 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Scholar Rock in the 4th quarter valued at about $2,625,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Stock Down 5.3%

NASDAQ SRRK traded down $1.61 on Tuesday, hitting $28.86. 1,456,907 shares of the stock were exchanged, compared to its average volume of 1,272,554. The company has a market cap of $2.74 billion, a PE ratio of -12.28 and a beta of 0.37. The company has a 50-day moving average price of $30.55 and a 200-day moving average price of $35.95. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the business earned ($0.59) earnings per share. Sell-side analysts anticipate that Scholar Rock will post -2.42 EPS for the current fiscal year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.